Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854408 | 0.91 | HPGD (0.46) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL1848790 | 0.85 | KMO (0.43) | NPC1SMN1; SMN2RAB9A | |
| SCHEMBL16734746 | 0.83 | TP53 (0.58) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL16733080 | 0.82 | TP53 (0.44) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL1856053 | 0.82 | GPR52 (0.56) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL1847641 | 0.79 | JMJD6 (0.47) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL1849559 | 0.73 | GPR52 (0.52) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL29617015 | 0.71 | TP53 (0.62) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL1856476 | 0.71 | GPR52 (0.51) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL1852323 | 0.71 | GPR52 (0.49) | NPC1SMN1; SMN2RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | NPC1 2479/4885SMN1; SMN2 4263/4885RAB9A 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.